前列地尔联合低分子肝素治疗不稳定型心绞痛的临床观察

Clinical observation on the treatment of unstable angina pectoris with low molecular weight heparin combined with alprostadil

目的观察前列地尔联合低分子肝素治疗不稳定型心绞痛(UAP)患者的临床疗效和不良反应。方法 78例UAP患者按治疗方法分为对照组和治疗组,每组39例。对照组给予低分子肝素钠治疗,同时给予阿司匹林和硝酸甘油等常规治疗,治疗组在对照组基础上联合应用前列地尔治疗,均治疗14 d。比较两组治疗前后心绞痛发作次数、持续时间、心电图改变及不良反应的发生情况。结果经14 d治疗后,治疗组患者心绞痛发作次数和持续时间均低于对照组,差异有统计学意义(P<0.05)。治疗组心电图改善情况优于对照组,差异有统计学意义(P<0.05)。治疗组的总有效率(94.87%)大于对照组(76.92%),差异有统计学意义(P<0.05)。治疗期间两组患者均未出现明显的不良反应。结论在低分子肝素钠常规治疗基础上联合应用前列地尔对不稳定型心绞痛具有显著疗效。

Objective To observe the clinical efficacy and adverse reactions of low molecular heparin combined with alprostadil in the treatment of unstable angina（UAP） patients. Methods 78 patients with UAP were divided into control group and treatment group by treatment methods, with 39 cases in each group. The control group was treated with low molecular weight heparin sodium and conventional treatment such as aspirin and nitroglycerin. The treatment group was treated with alproterol on the basis of the control group and both groups treated with 14 days. The incidence of angina pectoris, duration, ECG changes and adverse reactions were compared between the two groups before and after treatment. Results After treatment, the number of angina and duration of angina in the treatment group were lower than that in the control group, and the difference was statistically significant（P〈0.05）. The improvement of electrocardiogram was better than the control group, and the difference was statistically significant（P〈0.05）. The total effective rate of treatment group（94.87%） was better than that of the control group（76.92%）, and the difference was statistically significant（P〈0.05）. No obvious adverse reactions were observed between the two groups during the treatment. Conclusions The combined application of alprosite in the conventional treatment of low molecular heparin sodium has significant effect on unstable angina pectoris.